Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
DualityBio tries to float again
The group expects to raise nearly $170m.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
